Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Algoritmo de tratamiento COVID-19 centrado en identificación temprana de factores de riesgo / COVID-19 treatment algorithm focused on early identification of risk factors
Resumen
Resumen
El coronavirus 2 asociado al síndrome respiratorio agudo severo (SARS-CoV-2) es el causante de la enfermedad respiratoria denominada COVID-19 y del estado de emergencia sanitaria mundial. En la actualidad no existe tratamiento específico ni información científica suficiente para generar un consenso o guías internacionales únicos sobre cómo tratar la COVID-19. Se sugiere que adaptar las acciones de evaluación, monitorización y tratamiento de los pacientes con COVID-19, centradas en el conocimiento de la fisiopatología de la enfermedad y en los factores de riesgo conocidos, podría mejorar la presentación de los desenlaces adversos en los pacientes. En este trabajo se presenta un flujograma de atención y tratamiento para el paciente con COVID-19 durante la hospitalización, centrado en la identificación de la etapa de la enfermedad, la revaloración constante con énfasis en la identificación temprana de los factores de mal pronóstico y propuestas del tratamiento de acuerdo con las guías actuales.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the respiratory disease called COVID-19 and of the state of global health emergency. Currently, there is no specific treatment or sufficient scientific information to generate consensus or unique international guidelines on how to treat COVID-19. It is suggested that adapting the actions of evaluation, monitoring and treatment of patients with COVID-19, focused on the knowledge of the pathophysiology of the disease and on the known risk factors, could improve the presentation of adverse outcomes in patients. In this work, a flow chart of care and treatment for the patient with COVID-19 during hospitalization is presented, focused on the identification of the stage of the disease, constant reassessment with emphasis on the early identification of poor prognosis factors and treatment proposals according to current guidelines.
Palabras clave
Referencias
Helmy A, Fawzy M, Elaswad A, Sobieh A, Kenney S, Shehata A. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. J Clin Med 2020;1225(9). doi: 10.3390/jcm9041225
World Health Organization. Clinical management of COVID-19. Interim guidance. Última actualización 27 de mayo de 2020. [Internet, consultado el 22 julio 2020]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance-publications.
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health [Internet]. Última actualización 17 de julio de 2020 [consultado el 22 julio 2020]. Disponible en: https://www.covid19treatmentguidelines.nih.gov/ about-the-guidelines/whats-new/
Zheng C, Wang J, Guo H, Lu Z, Ma Y, Zhu Y, et al. Risk-adapted Treatment Strategy For COVID-19 Patients. Int J Infect Dis. 2020;94:74-77. doi: 10.1016/j. ijid.2020.03.047.
Galluccio F, Ergonenc T, Garcia A, Ei-Sayed A, Pérez M, Aguilar R. Treatment algorithm for COVID-19: a multidisciplinary point of view. Clin Rheumatol. 2020. doi:10.1007/ s10067-020-05179-0.
Gandhi R, Lynch J, Del Río C. Mild or Moderate Covid-19. N Engl J Med 2020;10.1056/NEJMcp2009249. doi: 10.1056/NEJMcp2009249.
Berlin D, Gulick R, Martinez F. Severe Covid-19. N Engl J Med 2020;10.1056/NEJMcp2009575. doi: 10.1056/NEJMcp2009575.
Instituto Mexicano del Seguro Social. Algoritmos internos para atención del COVID-19. Ciudad de México: IMSS; 25 de junio de 2020 [consultado el 22 julio 2020]. Disponible en: http://educacionensalud.imss.gob.mx/es/coronavirus/algoritmos.
Zhou F, Yu T, Ronghui D, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.
Bikdeli B, Madhavan M, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, an Follow-up. J Am Coll Cardiol. 2020;75(23):2950-73.
Boukhris M, Hillani A, Moroni F, Salah M, Addad F, Harada-Ribeiro M, et al. Cardiovascular implications of the COVID-19 pandemic: a global perspective. Can J Cardiol. 2020. DOI: 10.1016/j.cjca.2020.05.018.
Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Critical Care. 2020;24:188.
Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;S0091- 6749(20)30495-4. doi: 10.1016/j.jaci.2020.04.006.
Xie J, Covassin N, Fan Z, Singh P, Gao W, Li G, et al. Association Between Hypoxemia and Mortality in Patients With COVID-19. Mayo Clin Proc. 2020;95(6):1138- 1147. doi: 10.1016/j.mayocp.2020.04.006.
Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. Journal of Infection 2020;80:e1–e6. doi: 10.1016/j.jinf.2020.03.004.
Chen G, Zhao J, Ning Q. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest 2020. doi: 10.1172/JCI137244.
Buckner F, McCulloch D, Atluri V, Blain M, McGuffin S, Nalla A, et al. Clinical Features and Outcomes of 105 Hospitalized patients with COVID-19 in Seattle, Washington. doi: 10.1093/cid/ciaa632/5842263.
Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine and Growth Factor Reviews. 09 abril 2020. doi: 10.1016/j.cytogfr.2020.04.002.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in whuan, China. JAMA Intern Med. 2020;e200994.
Kermali M, Kaur R, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19 – A systematic review. Life Sciences. 2020. doi: 10.1016/j. lfs.2020.117788.20
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020:ciaa248. doi: 10.1093/cid/ciaa248.
Lagunas F. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): A meta‐analysis. J Med Virol. 2020;1-2. doi: 10.1002/jmv.25819.
Liu Y, Du X, Chen J, Jin Y, Peng L, Wang H, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection. 2020;17:28. doi: 10.1016/j.jinf.2020.04.002.
Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763.
Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, et al. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/S0140-6736(20)30628-0.
Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. Invest Radiol. 2020;55: 00–00). doi: 10.1097/RLI.0000000000000672.
Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients with COVID-19 Pneumonia: The CALL Score. Clinical Infectious Diseases. 2020;71(6):1393-99. doi: 10.1093/cid/ciaa414
Mejia-Vilet JM, Cordova-Sanchez BM, Fernández-Camargo D, Medez-Perez RA, Morales-Buenrostro LE, Hernandez-Gilsoul T. A Risk Score to Predict Admission to Intensive Care Unit in Patients With COVID-19: The ABC-GOALS Score. medRxiv. 2020. doi: 10.1101/2020.05.12.20099416.
Bhimraj A, Morgan R, Hirsch A, Lavergne V, Baden L, ChiChung V, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID- 19. Version 1.0.4 [consultado el 22 de julio de 2020]. Disponible en https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management.
The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. N Engl J Med. 2020. doi: 10.1056/NEJMoa2021436.
Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A, et al. Remdesivir for the treatment of Covid-19 — preliminary report. N Engl J Med 2020. doi: 10.1056/ NEJMoa2007764.
Piantoni S, Patroni A, Toniati P, Furloni R, Franceschini F, Andreoli L, et al. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease. Rheumatology (Oxford). 2020;keaa217. doi:10.1093/rheumatology/keaa217.
Montealegre-Gomez G, Garavito E, Gómez A, Rojas A, Parra R. Colchicina: una herramienta terapeutica potencial frente a COVID-19. Experiencia en 5 pacientes. Reumatología Clínica 2020. doi: 10.1016/j.reuma.2020.05.001.
Deftereos S, Giannopoulos G, Vrachatis D, Siasos G, Giotaki S, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. The GRECCO-19 Randomized Clinical Trial. Jama Netw Open 2020;3(6):e2013136. doi: 10.101/ jamanetworkopen.2020.13136.
European Centre for Disease Prevention and Control. Technical Report. Novel coronavirus (SARS-CoV-2). Discharge criteria for confirmed COVID-19 cases – When is it safe to discharge COVID-19 cases from the hospital or end home isolation?
DOI: https://doi.org/10.24875/RMIMSS.M20000142
Enlaces refback
- No hay ningún enlace refback.